Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AbbVie CD38 compound 16
- Development stage
- Unknown
- Lead developer
- AbbVie
01
Overview
AbbVie CD38 compound 16: sourced facts only. name: "These efforts led to the discovery of brain-penetrant CD38 inhibitor 16, which was evaluated in vivo and demonstrated dose-dependent increases of NAD+ measured in mouse brain and lung tissue samples following oral doses ranging from 3 to 100 mg/kg." [PMID:42866454]; target: "These efforts led to the discovery of brain-penetrant CD38 inhibitor 16, which was evaluated in vivo and demonstrated dose-dependent increases of NAD+ measured in mouse brain and lung tissue samples following oral doses ranging from 3 to 100 mg/kg." [PMID:42866454]; developer: "AbbVie, Inc., North Chicago, Illinois 60064, United States." [PMID:42866454]
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on AbbVie CD38 compound 16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AbbVie CD38 compound 16.